COMP <GO>
MGX vs BSEM // ALTMAN Z-SCORE & DEBT/EQUITY
Metagenomi Therapeutics Inc. (NASDAQ) VS. BioStem Technologies Inc. (NASDAQ) • 15-METRIC TALLY: MGX 2
— BSEM 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BSEM
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
balance-sheet
0.20
LAST: $1.29 (-14.57%) • MKT CAP: $24.1M
balance-sheet
2.44
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGX VS. BSEM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGX | BSEM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 93.60% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -5.70% | -29.30 | BSEM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -1.50% | -58.50 | BSEM | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -13.90% | -46.10 | BSEM | /net-margins <GO> |
| Revenue Growth (YoY) | -51.80% | -31.80% | -20.00 | BSEM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 2.44 | -2.24 | BSEM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 5/9 | -4.00 | BSEM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 21.9 | +9.01 | MGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $24.1M | $7.3M | MGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGX REV | BSEM REV | MGX GROSS % | BSEM GROSS % | MGX FCF | BSEM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.2M | $47.5M | — | 93.6% | -$89.5M | $6.6M |
| FY 2024 | $52.3M | $69.7M | — | 80.3% | -$112.2M | $24.0M |
| FY 2023 | $44.8M | — | — | — | -$91.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGX // BETA —
BSEM // BETA —